Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Alzheimer’s disease: KOL Insight

Product Code:
Latest Update:
May 2013

In 2012, the Alzheimer’s disease (AD) market was dealt a huge blow following negative results from pivotal Phase III trials of Pfizer and J&J’s bapineuzumab and the intravenous formulation of the drug was discontinued. Expectations for beta-amyloid theory were low following this failure; however results from Eli Lilly’s solanezumab have offered a glimmer of hope for the AD community. Although missing its primary endpoints, pooled analysis of solanezumab data in mild patients showed a statistical significant slowdown of cognitive decline.

With novel therapies slowly emerging from the pipeline, such as beta secretase and tau therapies, and positive research into biomarkers to aid early AD diagnosis there is renewed hope as the market enters a new phase of development.

The KOL Insight module of Alzheimer’s Disease: Beta-amyloid light fases to leave development hole is compiled from exclusive, in-depth interviews with the world’s leading KOLs in AD. It identifies and analyses the major factors, advances and trends currently influencing the AD treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future AD management.

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how AD clinical research will shape the future market.

Click here for sample pages

Key Benefits

Alzheimer’s disease: Beta-amyloid light fades to leave development hole examines the most prominent insights gained from the field’s key opinion leaders. The results of FirstWord’s research and analysis will help you to:

  • Comprehend the current trends driving and shaping the global AD market
  • Understand the future landscape and how new classes will fit into the treatment algorithm
  • Assess the commercial and clinical potential of the pipeline beta-amyloid and BACE inhibitors
  • Develop planning strategies based from KOL insight
  • Identify the unmet needs and opportunities for disease management
  • Evaluate the performance of companies with the most robust new product pipelines
  • Recognise the key factors KOLs predict will drive future treatment trends

Alzheimer’s disease: Beta-amyloid light fades to leave development hole
answers key questions including:

  • What do KOLs make of the sola and bapi failures?
  • What are the current unmet needs and major challenges in AD treatment?
  • What are the most promising late-stage classes in development?
  • Which therapy are KOLs eagerly awaiting?
  • How will the beta-amyloid and BACE inhibitors be positioned in the AD market?
  • In what ways could eventual biomarkers improve future AD disease management?
  • How will treatment of AD look in the future?
  • How do KOLs think the pricing environment will shape the uptake of new AD treatments?
  • What clinical research trends do KOLs predict for future AD therapies?

Click here for sample pages

Alzheimer’s Disease Panel of Key Opinion Leaders

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. The AD panel assembled for this Therapy Trends research is drawn from North America and Europe professionals:

  • Assistant Professor at Department of Neurology and Neurological Sciences, Stanford, California, USA
  • Chief Medical/Scientific Officer of Sun Health Research Institute, Sun City, Arizona, USA
  • Assistant Professor of Neurosciences at the University of California, San Diego, USA
  • Professor at Columbia University Medical Center in the Departments of Psychiatry, Neurology, and Pharmacology, New York, USA
  • Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California, California, USA
  • Associate Professor of clinical neurology and neuroscience at New York Presbyterian Hospital and Weill Cornell Medical College, New York, USA
  • Adjunct Assistant Professor, Department of Neurology, UCLA, Los Angeles, USA
  • Head of the department in Geriatric Psychiatry at the University of Heidelberg, Heidelberg, Germany
  • Neurologist, Department of Clinical Neurosciences at University of Cambridge, Cambridge, UK
  • Director, CNS Research at Chiesi Farmaceutici, Milan, Italy
  • Neurologist at Karolinska Institutet, Stockholm, Sweden

Click here for sample pages

Event Assessments

Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.

Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.


This report provides a qualitative overview of the current and future Alzheimer’s disease (AD) market. Information was gathered from telephone discussions held with twelve key opinion leaders (KOLs), from across the major AD markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also dictate the dynamics of Pharma markets in other countries.

In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.

Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for AD, the future of AD drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing AD drug classes, the cost of newer drugs and other concerns in the therapy area.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved